Acquisition - May 24, 2019
Amgen to buy Nuevolution for $166.8 million
Amgen has agreed to buy the biopharmaceutical company Nuevolution AB for 1.61 billion Swedish crowns ($166.8 million) to boost its position in drug discovery. Nuevolution said its board unanimously recommended Amgen’s cash offer of 32.5 Swedish crowns per share, a premium of 168.6% to Nuevolution’s closing price on Tuesday, reported Reuters. The offer from Amgen […]
Acquisition - May 7, 2019
Lundbeck to acquire Abide Therapeutics
Lundbeck and Abide Therapeutics have announced signing of a definitive agreement in which Lundbeck LLC has agreed to acquire Abide. Under the terms of the agreement, Lundbeck may pay USD 250 million (approximately DKK 1.65 billion) upfront with a commitment to pay future development and sales milestones to the group of current owners of up […]
Acquisition - March 13, 2019
Fujifilm acquires Danish biologics unit from Biogen for $890 million
Japan’s Fujifilm Holdings Corp will acquire a drug making business from the U.S. based Biogen Inc for about $890 million. With this acquisition Fujifilm aims to accelerate the growth of its Bio CDMO business. Large-scale biologics manufacturing site located in Hillerød Fujifilm has entered into an agreement to acquire the Danish Biogen Manufacturing ApS, a […]
Acquisition - January 6, 2019
BMS acquires Celgene for $74 billion
Bristol-Myers Squibb (BMS) and Celgene have announced that they have entered into a definitive merger agreement under which BMS will acquire Celgene in a cash and stock transaction with an equity value of approximately $74 billion. Under the terms of the agreement, Celgene shareholders will receive 1.0 Bristol-Myers Squibb share and $50.00 in cash for […]
Acquisition - November 29, 2018
AddLife acquires Austrian Biomedica
The company is taking an important step in its expansion and internationalization strategy by acquiring Austrian Biomedica Medizinprodukte GmbH. Biomedica, which is the parent company of a group with sales of about EUR 65 million, engages in operations in 13 countries in Europe and has about 280 employees. Just like AddLife, Biomedica supplies products and […]
Acquisition - November 13, 2018
AstraZeneca divests US Synagis rights to Sobi
AstraZeneca has agreed to sell US rights to Synagis (palivizumab) used for the prevention of serious lower respiratory tract infection (LRTI) caused by respiratory syncytial virus (RSV) to Swedish Orphan Biovitrum AB (Sobi). Sobi will commercialise Synagis in the US and around 130 AstraZeneca employees will transfer to Sobi as part of the transaction. Sobi will […]
